Brought to you by

NeoSan gets US rights to Lilly's Darvon and Darvocet N
26 Mar 2002
Executive Summary
AaiPharma's commercialization unit NeoSan Pharmaceuticals acquired US rights to Eli Lilly's Darvon (propoxyphene hydrochloride) and Darvocet N (propoxyphene napsylate with acetaminophen) line of pain management products.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Product Purchase
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com